Drug Type siRNA |
Synonyms |
Target |
Mechanism lipoprotein(a) inhibitors, RNA interference |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Start Date04 Sep 2024 |
Sponsor / Collaborator |
Start Date02 Jul 2024 |
Sponsor / Collaborator |
Start Date05 Mar 2024 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Phase 3 | NL | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | IN | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | GB | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | JP | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | RO | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | CN | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | AR | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | TW | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | BR | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | PL | 05 Mar 2024 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |